Asterand: Learning from Failure Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

This case chronicles the problems of creating innovative banking services tissues to accelerate research and development processes, biotechnology and pharmaceutical companies worldwide. Asterand two main challenges to achieve a standardized approach to the collection of tissue samples in hospitals around the world and achieve the highest possible quality of tissue samples sent to its major clients, Amgen. Despite the identified need for high-quality tissue samples, Asterand experiencing some quality control problems in their processes and procedures. Tissue samples were packed poorly labeled incorrectly or taken at the wrong time or in the wrong place. In addition, there were problems with the quality of the analysis of RNA from the sample, which was the deciding factor in the usability of a sample of tissue for research and development of new treatments and drugs. The head of pathology at the California facility Amgen was threatening to terminate their existing order and failure to communicate Asterand for all employees, which will have a devastating ripple effect in the industry and is likely to destroy the possibility for any future orders with Asterand. If this happened, Asterand not be able to provide customer contracts and the risk of losing investors and bankrupt. "Hide
by Anne Snowdon, Hannah Standing Rasmussen, David Maslach Source: Richard Ivey School of Business Foundation 11 pages. Publication Date: October 29, 2012. Prod. #: W12286-PDF-ENG